A Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen
Clinical trial NCT00932373 · COMPLETED
Trial details
- NCT number
- NCT00932373
- Sponsor
- Genentech, Inc.
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2006-04-01
- Primary completion
- 2009-06-01
- Enrollment
- 54
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.